Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXCO-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Group 2 | EXPERIMENTAL | Dose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Group 3 | EXPERIMENTAL | Dose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Placebo | PLACEBO_COMPARATOR | Sodium Chloride administered IM by needle and syringe at Day 1 and Week 8 |
| Name | Type | Description |
|---|---|---|
| VXCO-102 | BIOLOGICAL | Sterile liquid for injection |
| Placebo | BIOLOGICAL | 0.9% sodium chloride (BP grade) |
Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that ...
VXCO-102 is an investigational monoclonal antibody being developed by Eli Lilly and Company for Epstein-Barr virus, or EBV. It is in Phase 1 clinical development. It is a biologic therapy rather than a small molecule, and it is being studied in a single recruiting clinical trial.
VXCO-102 is being developed for Epstein-Barr virus (EBV) infection. Its only listed clinical program is a Phase 1 study in EBV. Because the program is at the Phase 1 stage, VXCO-102 remains investigational and has not been established as a treatment for any condition.
VXCO-102 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 program for the monoclonal antibody in Epstein-Barr virus.
VXCO-102 is in Phase 1 clinical development. It is investigational and is not approved for any indication. The program consists of one Phase 1 trial that is currently recruiting, with no completed trials reported.
VXCO-102 is being studied in trial NCT07557602, a Phase 1 study titled mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults. The trial is recruiting in Australia, is randomized, double-blind, and placebo-controlled, and plans to enroll 82 participants aged 18 years and older.
Yes. The Phase 1 trial of VXCO-102, NCT07557602, enrolls healthy volunteers rather than patients with an active disease. Participants must be at least 18 years old, and the study accepts all sexes. The trial is placebo-controlled, randomized, and double-blind, with planned enrollment of 82.